Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05348577
Title Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello-280)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

prostate adenocarcinoma

Therapies

Capivasertib + Docetaxel

Docetaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.